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Abstract
Genome-editing of human pluripotent stem cells (hPSCs) provides a genetically controlled and clinically relevant platform from which to
understand human development and investigate the pathophysiology of disease. By employing site-specific nucleases (SSNs) for genome
editing, the rapid derivation of new hPSC lines harboring specific genetic alterations in an otherwise isogenic setting becomes possible. Zinc
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 are the most commonly used SSNs. All of these nucleases function by introducing a double stranded DNA break at a specified
site, thereby promoting precise gene editing at a genomic locus. SSN-meditated genome editing exploits two of the cell's endogenous DNA
repair mechanisms, non-homologous end joining (NHEJ) and homology directed repair (HDR), to either introduce insertion/deletion mutations
or alter the genome using a homologous repair template at the site of the double stranded break. Electroporation of hPSCs is an efficient
means of transfecting SSNs and repair templates that incorporate transgenes such as fluorescent reporters and antibiotic resistance cassettes.
After electroporation, it is possible to isolate only those hPSCs that incorporated the repair construct by selecting for antibiotic resistance.
Mechanically separating hPSC colonies and confirming proper integration at the target site through genotyping allows for the isolation of
correctly targeted and genetically homogeneous cell lines. The validity of this protocol is demonstrated here by using all three SSN platforms to
incorporate EGFP and a puromycin resistance construct into the AAVS1 safe harbor locus in human pluripotent stem cells.
Video Link
The video component of this article can be found at http://www.jove.com/video/53583/
Introduction
Genome editing technologies are rapidly evolving into standard tools for molecular and cell biology 1. Genetic engineering of human pluripotent
stem cells (hPSCs) is of particular interest as hPSCs represent a self-renewing source of genetically intact primary human cells. hPSCs can be
differentiated into various cell types for disease modeling or as a source for transplantation therapies 2,3. Demonstrated here is a protocol that
utilizes three different types of site-specific nucleases (SSNs) in conjunction with endogenous DNA repair mechanisms for targeted integration
of a reporter construct at the AAVS1 locus. After transfection of SSNs into hPSCs, we demonstrate how to isolate isogenic cell populations
harboring the reporter.
The ability to manipulate genomes, specifically pluripotent stem cell genomes, using SSNs is not a new phenomenon as the utility of zinc
finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) for gene editing was demonstrated several years ago 4-10.
However, with the advent of S. pyogenes CRISPR/Cas9 technology 11-13, gene editing has become widely accessible 14. All SSNs introduce
a double stranded DNA break (DSB) at the specified target site 1,4,5,11 that is repaired by endogenous cellular mechanisms using either non-
homologous end-joining (NHEJ) or homology directed repair (HDR) 15. NHEJ is error-prone and can introduce frame shift mutations resulting
in loss of gene function, while HDR allows for novel elements to be introduced through the co-transfection of a repair template with the SSN.
While the underlying principles of DNA repair that facilitate gene editing are thought to be largely the same for each SSN, some differences
between the platforms can be noted. De novo design of ZFNs allows flexibility and nuclease optimization 16, however the use of publicly available
assembly libraries and screening tools to design individual ZFNs can be time consuming. Once the desired locus for ZFN-mediated targeting
is determined, ZFN pairs can be designed with the online tool ZiFit 17. After design, ZFNs can be modularly assembled through several rounds
of plasmid cloning 18. Alternatively, there are many commercially available, pre-validated ZFNs 19. TALE nucleases can also be designed using
online tools and publically available components 17,20. For example, TALENs can be rapidly assembled from blocks of five TALE repeats,
through FLASH assembly 21 or using PCR based hierarchical Golden Gate assembly 22. Ease of SSN design and speed of construction using
CRISPR/Cas9 have made genome editing a widely accessible tool. The short guide RNA-mediated targeting of CRISPR/Cas9 also allows for
multiplexing of guide RNAs to target several loci with a single construct 14. The design of Cas9 for gene editing requires only the identification
of a protospacer adjacent motif (PAM; an NGG trinucleotide for S. pyrogenes Cas9) proximal to the target locus. By inserting an oligonucleotide
corresponding to the 20 base pairs 5' of the PAM into the px330 plasmid 14, the construct can be assembled in one cloning step. In addition to
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S. pyogenes Cas9, Cas9 from N. meningitidis (NmCas9) that recognizes a 5′-NNNNGATT-3′ (PAM) has been shown to allow for efficient gene-
editing in hPSCs 23.
In addition to the differences in ease of SSN design, each platform has specific properties. For example, ZFNs and TALENs utilize the FokI
nuclease domain, which generates a four nucleotide 5' overhang 24 while Cas9 is thought to generate mostly blunt ended DSBs. ZFNs, TALENs,
and Cas9 differ in their protein stabilities, on-off rate on target DNA, and mode of DNA scanning, all of which could theoretically result in small
differences in the editing outcome 1. While further studies will be required to fully understand the consequences of these differences, we describe
here a protocol that is highly robust across all three platforms and can be used to readily generate genetically modified hPSCs.
Regardless of SSN choice, electroporation is a robust procedure to transfect SSNs and homology repair templates into hPSCs 25. The number of
surviving colonies after selection for antibiotic resistance depends on locus-specific parameters and the editing strategy (e.g., size of transgenic
insert and mode of selection). The protocol described here usually results in about 150-400 single-cell derived colonies.
Gene-editing at the AAVS1 locus using this protocol has previously been used to demonstrate the effectiveness of SSNs 4,5. The AAV-CAGGS-
EGFP repair template uses a gene trap strategy to confer puromycin resistance in a locus specific manner. Briefly, the repair template contains a
splice acceptor site upstream of the promoterless puromycin resistance cassette. Upon correct integration into the first intron of the PPP1R12C
gene at the AAVS1 locus, the resistance cassette is expressed from the edited gene's promoter. The robustness of this specific AAVS1 assay
allows us to compare the efficiency of each SSN platform.
Gene editing using SSNs is powerful given the ability to disrupt and/or alter theoretically any gene. Applying this strategy to hPSCs provides
versatility as hPSCs can be subsequently differentiated into a multitude of human cell types such as neurons 26, hepatocytes 27, and
cardiomyocytes 28. Additionally, the use of patient-derived induced pluripotent stem cells allows the repair or introduction of known disease-
causing mutations in a patient-specific genetic background 29, providing a platform from which to investigate disease mechanisms and test
therapeutics using a patient's own cells 30. In summary, gene editing in hPSCs is an efficient and versatile approach for investigating the basic
biology of human development and disease 31.
Protocol
The procedures described in this manuscript were reviewed and approved by the UC Berkeley Stem Cell Research Oversight Committee.
1. Prepare Stem Cells for Editing
1. Grow and culture human pluripotent stem cells (hPSCs) on a 6-well plate containing 2.4 × 106 cells/plate of mitomycin C-inactivated mouse
embryonic fibroblast (MEF) feeders grown on gelatin 32. Maintain hPSCs in 3 ml of human embryonic stem cell media per well (hESC media)
and grow in a 37 °C incubator with 3% O2/5% CO2.
 
Note: For the success of this protocol, it is not necessary to maintain hPSCs in a low-oxygen incubator; however it is important to note that
hPSCs proliferate faster in a high O2 environment, so times and cell numbers should be adjusted accordingly. It should also be noted that
hPSCs maintained in low oxygen have lower rates of spontaneous differentiation 33.
1. To make 500 ml hESC media combine 380 ml DMEM/F12, 75 ml Fetal Bovine Serum (FBS), 25 ml KnockOut Serum Replacement
(KSR). Add Glutamine (1 mM final concentration), 5 ml 100x Non-essential Amino Acids, 100 units/ml Penicillin-Streptomycin (P/S),
basic Fibroblast Growth Factor (bFGF) (4 ng/ml final concentration), and 2-mercaptoethanol (5.5 µM final concentration).
2. Change media by removing entire volume of media (3 ml) using a glass pipette and vacuum. Replace with 3 ml warm hESC media using a
serological pipette. Repeat media change every day until hPSCs are approximately 50% confluent (Day -1).
3. One day before targeting (Day -1), change hESC media, removing the old media and adding warm hESC media supplemented with 10 µM
Y-27632.
4. Also on Day -1, prepare one to two 6-well or 10 cm plates of drug resistant MEF feeder cells from DR4 mice (2.4 × 106 cells/plate) 34.
 
Note: In general, 6 well plates are advantageous over 10 cm plates, as they accommodate more media. 6 well plates also ensure that
different clones from different wells are independent. However, a 10 cm plate will allow easier picking, depending on the microscope available
for this process.
2. Editing Pluripotent Stem Cells
1. Prepare transfection solutions by pipetting 5 µg each of ZFN 1 and 2, TALEN 1 and 2, or 15 µg of the CRISPR/Cas9 px330 encoding plasmid
(Figure 1) into a 1.5 ml tube. Pipette 30 µg of the repair plasmid into this tube as well. Finally, pipette 1x Phosphate Buffered Saline (PBS)
into the tube to bring the volume up to 300 µl.
 
Note: Prepare plasmids as a midiprep (any kit is suitable) with a minimum concentration of 300 ng/µl in order to keep the total volume of the
transfection solution under 300 µl. It is not necessary to perform phenol/chloroform extraction, to linearize the plasmid, or to use an endotoxin
free plasmid prep kit.
2. Remove media from hPSCs using a glass pipette and vacuum. Pipette 2 ml warm 1x PBS into each well to wash the cells.
3. Remove the PBS immediately using a glass pipette and vacuum. Add 0.5 ml 0.25% Trypsin-EDTA solution directly onto cells in each well.
Place in the incubator (37 °C/5% CO2/3% O2) for approximately 10 min. or until feeder layer starts to lift off the plate.
4. Add 2 ml warm esWash media (470 ml DMEM/F12, 25 ml FBS, 100 units/ml P/S) to each well to stop the trypsin reaction.
5. Ensure that feeder cells come off as a sheet. Pipette the contents of each well into a single 50 ml conical tube, combining all wells. Triturate
cells using a 10 ml serological pipette. It is not necessary to break up the feeder layer; hPSCs will come off of the feeder layer by gentle
trituration. There should be about 15 ml of the cell suspension.
6. Add 25 ml of esWash media to the tube to bring the volume up to 40 ml total. Allow large feeder chunks to settle at the bottom of tube for 1-2
min. Remove the supernatant (~38 ml) from the tube using a serological pipette and deposit into a new 50 ml conical tube.
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7. Spin down for 5 min at 190 x g. Remove the supernatant from the tube using a glass pipette and vacuum. Be sure to not disturb the cell
pellet. Resuspend the cells in 500 µl 1x PBS. Combine with plasmid transfection solution prepared earlier. Count the cells at this step. Use
5-10 million cells per electroporation.
8. Pipette the entire 800 µl suspension into a 4 mm electroporation cuvette, place on ice for 3-5 min. Electroporate cells using the exponential
program on the electroporation system with the following parameters: 250 V, 500 µF, ∞ resistance, and 4 mm cuvette size. After
electroporation, place cuvette back on ice for 3 min.
 
Note: Observe the time constant of the electroporation on the electroporation system. The time constant varies with cell number and DNA
purity. Successful transfections usually have a time constant between 10-14 msec when using the listed conditions and a gene pulser II.
Lower electroporation efficiencies can occur when time constants varies from these values.
9. Resuspend electroporated cells in 18 ml warm hESC Media supplemented with 10 µM Y-27632. Plate 3 ml of this single cell suspension into
each well of a 6 well plate with DR4 feeder cells. Return to incubator (37 °C/5% CO2/3% O2).
3. Selection of Positive Colonies
1. Day 2, remove all media using a glass pipette and vacuum. Replace with 3 ml of warm hESC media supplemented with 10 µM Y-27632. Day
3, remove all media using a glass pipette and vacuum. Replace with 3 ml of warm hESC media without including Y-27632. Day 4, remove
all media using a glass pipette and vacuum. Replace with 3 ml warm hESC media supplemented with antibiotics for selection. Return to
incubator (37 °C/5% CO2/3% O2).
 
Note: The type of antibiotic used will depend on the resistance cassette included in the repair template. When working with WIBR#3 hPSCs
(NIH registry 0079), 0.5 µg/ml puromycin, 70 µg/ml G418 (geneticin), and 35 µg/ml hygromycin have been used successfully. Concentrations
for selection should be determined empirically by establishing the minimal concentration of antibiotic needed to kill wild-type cells within
approximately one week.
2. Days 5-12, change media daily, replacing old media each time with warm hESC media supplemented with antibiotics.
 
Note: Expect a large amount of cell death. Individual colonies will become apparent around day 8-10. Regular hESC media without antibiotics
can be used after 12-14 days of continuous selection. If cell density is high or cell death is slow, acidification of the media should be avoided
and it may be necessary to increase the media volume (up to 4-5 ml) during the first few days of selection.
4. Picking Selected Colonies (Day 12-14)
1. Observe colonies on day 12-14. Observe the colonies that are ready to pick on a dissection microscope and ensure that they do not
contain cells that are starting to differentiate. The approximate size should be 800-1,200 µM. If colonies reach this size before day 12, it is
recommended that they should be picked then.
 
Note: For each targeting experiment, pick as many colonies as necessary to ensure the desired genotype is isolated. As an example, AAVS1
editing with the AAV-CAGGS-EGFP repair template has shown consistently robust integration, and requires only 12-24 colonies to be picked
to obtain approximately 5-10 heterozygously targeted clones. Other targeting experiments may require more colonies to be picked (Table 1).
The frequency of correct targeting events depends on factors such as the efficiency of the SSN to introduce a DSB, the size of insert, and the
selection strategy. In the case of the gene trap approach for the AAVS1 locus presented here, the selection marker is only expressed when
correctly integrated at the target site, reducing the number of colonies required to obtain a properly targeted clone.
2. One day before picking, prepare 12-well plates of MEFs (2.4 × 106 cells/plate, one well will be used for each colony picked).
3. On the day of picking, remove all media from the 12 well MEF plates using a glass pipette and vacuum and replace with 1 ml hESC media.
Also on day of picking, change hESC media on the 6 well plates that are going to be picked.
4. Pull glass pipettes for mechanical dissociation of individual colonies from the feeder layer. Lower the pipettes over an in-hood Bunsen burner
and softened at the expansion point until glass is malleable. Quickly remove from flame and pull the pipette apart creating an angular point.
Break the point approximately 2 cm from the bent axis, leaving a narrow channel. Polish the end of the channel by exposing to flame for 1-2
sec.
 
Note: Optionally pick colonies a p20 pipet tip, however, this may reduce the clonality of the culture, as the dull tip may dislodge greater
amounts of cells from each colony into the media, potentially contaminating subsequent pickings.
5. Assemble picking device by taking a p1000 filter pipette tip and attaching a suction bulb to the narrow end. Insert the pulled glass pipette in
the wide end.
6. Place a 6-well plate of hPSCs to be picked on the stage of a dissection microscope mounted in a tissue culture hood. Compress the bulb of
the picking device and gently excise and cut an individual colony into 10-20 equally sized pieces, taking care not to release pieces into the
media. Take excised hPSC pieces of the colony into the pipette by releasing the bulb. Try to take as little media as possible while transferring.
7. Transfer the individual colony to a single well of a 12-well MEF plate, compressing the bulb again directly into the well, releasing the now
broken colony. Label each well to allow unique identification of single-cell derived clones. Repeat for as many colonies as necessary,
changing the glass pipette each time.
 
Note: Picking colonies may take some time to learn. It is recommended that the experimenter practice on some control cells before trying to
isolate targeted colonies.
8. Return 12 well plates to the incubator (37 °C/3% O2/5% CO2), gently rocking the plate first to avoid accumulation of cells in the middle of each
well.
9. The next day and each subsequent day, remove full volume of media using a glass pipette and vacuum and replace with 1.5 ml of warm
hESC media until cells are about 50% confluent (this usually takes 10-12 days).
10. After 10-12 days, pick one to two colonies from each well and transfer to new 12-well MEF plates repeating steps 4.1-4.8 to generate a
replica plate.
11. Extract DNA (see below) from the remaining colonies in each well of the original MEF plates.
1. Remove media from all wells using a glass pipette and vacuum. Pipette 1 ml 1x PBS onto each well to wash cells. Remove PBS using
glass pipette and vacuum. Pipette 250 µl of cell lysis buffer (final concentrations in H2O: 10 mM Tris HCl, 5 mM EDTA, 0.2% SDS, 200
mM NaCl, 0.08 mg/ml Proteinase-K) onto each well. Place in incubator (37 °C/3% O2/5% CO2) O/N.
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2. The next day, pipette contents of each well into individual 1.5 ml tubes. Pipette 250 µl of isopropyl alcohol into each tube to precipitate
the DNA. Shake tube vigorously. A white precipitate should be visible.
3. Spin each tube down for 3 min at 13,000 rpm in a table top centrifuge. After spin down, discard supernatant by decanting into liquid
waste. A small DNA pellet should remain stuck to the bottom of the tube. Pipette 250 µl of 70% ethanol into each tube to wash the DNA
pellet. Shake vigorously. Spin each tube down for 3 min at 13,000 rpm in a table top centrifuge.
4. After spinning down, discard supernatant by decanting into liquid waste. A small DNA pellet should remain stuck to the bottom of the
tube. Pipette out the remainder of the supernatant so there is no liquid left in the tube. Leave tube open to dry on benchtop for 5-10
min. After drying, resuspend DNA in 250 µl TE buffer. Place at 37 °C for 6 hr to allow DNA to dissolve.
12. Genotype each sample using a pre-optimized PCR or southern blot strategy.
 
Note: For AAVS1 targeting using the AAV-CAGGS-EGFP repair template, the southern blot strategy can be found in Hockemeyer et al., 2009
4. A comprehensive southern blotting protocol can be found in Southern, 2006 35. For multiplex PCR genotyping of the same experiment,
primers and conditions can be found in Table 2 36.
13. Discard wells that are not properly targeted and continue changing hESC media on properly targeted cells every day. Freeze down the cells
when they are approximately 50% confluent, see below for freezing protocol.
1. One day before freezing, change hESC media, removing the old media and adding warm hESC media supplemented with 10 µM
Y-27632.
2. On the day of freezing prepare 0.5 ml each of solution A and solution B per well of a 12-well plate that is being frozen down in two
15 ml conical tubes. Place solutions on ice. Solution A: 50% hESC media and 50% FBS; Solution B: 80% FBS and 20% Dimethyl
Sulfoxide (DMSO).
3. Dissociate hPSC colonies into single cells before freezing. Follow steps 2.2-2.8 to do this, scaling volumes accordingly. Fully
resuspend cell pellet in 0.5 ml of solution A.
4. Add 0.5 ml solution B to cell suspension, pipette up and down to make cell suspension homogenous. Take the total volume of the cell
suspension (~1 ml) and deposit into a 2 ml cryotube. Screw cap on tightly.
5. Place cryotube in a -80 °C freezer O/N. The day after freezing, remove frozen cells from -80 °C freezer and immediately place into
liquid nitrogen tank for long-term storage.
Representative Results
Here we demonstrate a protocol compatible with three different SSN platforms to create genetically engineered hPSC lines. We targeted
WIBR#3 human embryonic stem cells at the AAVS1 locus using previously published ZFNs 4, TALENs 5 and CRISPR/Cas9s 37 using a repair
template that introduces an EGFP reporter and a puromycin resistance cassette 4.
We cultured our hPSCs on MEFs for a cell culture workflow permitting the maintenance and expansion of undifferentiated hPSCs (Figure 2), that
is also cost effective and scalable. If cells are grown longer than necessary there is a risk of increased differentiation, reducing the number of
pluripotent cells that are transfected and consequently the number of correctly targeted hPSC colonies obtained.
We electroporated 5.0 x 106 cells per SSN platform and plated the cells from each targeting onto a single 6 well plate of DR4 MEFs. After
selection, each platform resulted in EGFP-positive colonies (Figure 3) and a combination of untargeted, homozygously targeted and
heterozygously targeted clones (Figure 4A,B; Table 3). Under the conditions presented here, we find that the AAVS1 TALENs resulted in the
most EGFP-positive clones. The repair template used for this experiment consists of a splice acceptor site upstream of the EGFP reporter and
puromycin resistance cassette. Using this "gene-trap" strategy (Figure 1), the construct should insert into the first intron of the AAVS1 locus,
using the endogenous promoter to drive expression of the puromycin-resistance cassette. The lack of a promoter driving the expression of the
puromycin resistance gene within the repair template should prevent expression in the event of random integration.
Therefore, we expect that all puromycin-resistant clones would be targeted at the AAVS1 site. It should be noted that a subset of clones carry
aberrant integrations in the AAVS1 locus that are detectable by Southern blot using an internal probe, but not by most PCR strategies (Figure
1; Figure 4C) 4. These integration events are most likely the result of heterologous targeting events leading to multiple integrations of the donor
plasmid 4. We picked 24 colonies from each SSN experiment and found that all platforms had very high targeting efficiencies and showed only
minimal differences. As interrogated by PCR, CRISPR/Cas9 yielded the most correctly targeted clones while the TALEN platform had the most
homozygously targeted clones (Table 3).
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Figure 1. Schematic of gene edited AAVS1 locus using the AAV-CAGGS-EGFP repair template. Modified from Hockemeyer et al., 2009.
Please click here to view a larger version of this figure.
 
Figure 2. Colonies of WIBR#3 cells. Representative bright field images of colonies of WIBR#3 human embryonic stem cells prior to targeting.
Note the lack of differentiation and the clear separation from the feeder layer in an ideal colony (left) as opposed to a non-ideal one (right).
Please click here to view a larger version of this figure.
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Figure 3. EGFP-positive WIBR#3 cells. Representative images of WIBR#3 cells targeted with an EGFP-expressing repair template at the
AAVS1 locus. Images of representative colonies edited with ZFNs, TALENs and CRISPR/Cas9 are shown. Please click here to view a larger
version of this figure.
 
Figure 4. Genotyping strategies to confirm correct targeting. (A) Representative PCR genotyping results showing untargeted, heterozygous
and homozygous targeted clones across the three SSN platforms. WT CTL=wild-type control. (B) Representative Southern blot results showing
a heterozygous targeted clone and a homozygous targeted clone detected with a 3' external probe. Fragment sizes: WT-6.5 kb, Edited-6.9
kb. (C) Representative Southern blot results showing a properly edited clone and a heterozygous clone with a non-random double-integration.
Fragment sizes: Properly edited-6.9 kb, aberrant additional integration-5 kb. Please click here to view a larger version of this figure.
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Study Gene Targeted Platform Repair template type # of clones picked Targeting efficiency
Sexton et al., 2014 TPP1 ZFN GFP-Puro unreported unreported
Sexton et al., 2014 TERT ZFN Hygromycin unreported unreported
Hockemeyer et al.,
2009
POU5F1 ZFN GFP-Puro 31 39.0%
Hockemeyer et al.,
2009
PITX3 ZFN GFP-Puro 74 14.9%
Hockemeyer et al.,
2011
POU5F1 TALEN GFP-Puro 68 91.0%
Hockemeyer et al.,
2011
PITX3 TALEN GFP-Puro 96 13.0%
Merkle et al., 2015 VASA Cas9 Reporter-Geneticin 139 94.0%
Merkle et al., 2015 CRH Cas9 Reporter-Geneticin 30 93.0%
Merkle et al., 2015 HCRT Cas9 Reporter-Geneticin 154 92.0%
Merkle et al., 2015 HMX2 Cas9 Reporter-Geneticin 11 45.0%
Forster et al., 2014 LRG5-Nterm ZFN GFP-Puro unreported 30.0%
Forster et al., 2014 LRG5-Cterm ZFN GFP-Puro unreported 14.0%
Soldner et al., 2011 SNCA ZFN Puro 96 1.0%
Table 1. Description of other genes targeted using this method, with corresponding targeting efficiencies taken from previously
published studies. 4,5,38-41
Locus Sequence Notes
AAVS1-F primer CTCTAACGCTGCCGTCTCTC PCR conditions: Tm = 57 °C, 35 cycles
AAVS1-WT-R primer GCTTCTCCTCTTGGGAAGTG WT band: 1273 bp
AAVS1-Targeted-R primer CGTCACCGCATGTTAGAAGA Targeted band: 992 bp
T2-Cas9-guide GGGCCACTAGGGACAGGAT From Mali et al., 2013
AAVS1-ZFN-Right TAGGGACAGGAT From Hockemeyer et al., 2009
AAVS1-ZFN-Left TGGGGTGTCACC From Hockemeyer et al., 2009
AAVS1-TALEN-Right TCCTAACCACTGTCTTT From Hockemeyer et al., 2011
AAVS1-TALEN-Left CCCCTCCACCCCACAGT From Hockemeyer et al., 2011
Table 2. List of primers and SSN targeting sequences.
Targeting Construct Number of EGFP+ Colonies Targeted picked clones (PCR
verified)
Previous Reported Correct
Targeting Efficiency (by
Southern blot)
ZFN 150 86.9% (73.9% het/ 13.0 % homo) 56% (50% het/6% homo)
TALEN 412 91.3% (47.8% het/39.1% homo) 47% (37.5% het/9.3% homo)
CRISPR-Cas9 235 95.7 % (69.5% het/26.3% homo) unreported
Table 3. Comparative numbers of EGFP-positive and targeted TALEN, ZFN and CRISPR/Cas9 human stem cell colonies. PCR verified
integrations at the AAVS1 locus for this experiment are compared to Southern blot verified proper single integrations in previous experiments 4,5.
Discussion
The method presented here for isolating homogenous populations of gene-edited human pluripotent stem cells is a powerful approach for
generating isogenic hPSC lines that differ only at the targeted locus. These cells are an ideal system for probing the mechanisms of human
cellular differentiation and development as well as for understanding the pathophysiology of monogenic diseases in a controlled genetic
setting. As demonstrated here, it is possible to use three independent SSN design strategies (ZFNs, TALENs, and CRISPR/Cas9) to achieve
targeted integration at the AAVS1 locus. Each of these methodologies has its own advantages and disadvantages. A potential advantage of
ZFNs and, to some extent, TALENs is their design flexibility, which allows iterative engineering in order to improve the DNA binding domains
of individual nucleases 42. This nuclease optimization could increase the specificity of ZFNs and TALENs beyond what is achievable with the
CRISPR/Cas9 system. Such selectivity may be important for clinical applications requiring a high degree of target specificity. The primary
advantage of the CRISPR/Cas9 system is its ease of use. Although TALEN and ZFN construction kits have been made available to the public
(i.e., through Addgene 21), CRISPR/Cas9-based SSNs are significantly easier to construct, as the only necessary customization is a 20 base pair
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oligonucleotide (when using the px330 plasmid design 14). This simplicity proves to be advantageous for research labs looking to include genome
editing in their studies.
There are alternative transfection techniques, including nucleofection 43, to create gene-edited hPSC lines; however electroporation has been
shown to be consistent and cost effective 4,5,25. Nucleofection can be used to directly transfect Cas9-guide RNA ribonucleoprotein complexes
into the nucleus, increasing the SSN efficiency and fidelity 44. Growing hPSCs on MEFs is a robust and inexpensive method to maintain hPSCs
in a pluripotent state without excessive differentiation. In addition, it allows for the easy isolation of genetically identical colonies. Alternatively, it
is possible to culture hPSCs without MEFs, however these culture conditions can be more expensive than feeder based cultures. Furthermore,
the whole process is scalable, allowing for the isolation of very rare editing events or the generation of many distinct cell lines in parallel editing
experiments.
The protocol described here is robust; however there are several key steps that affect the efficiency with which correctly edited clones can be
obtained. The most critical component for this method is having high quality MEFs and drug resistant DR4 MEFs. The survival of single hPSCs
is tenuous, and low-quality MEFs will impede the isolation of undifferentiated hPSC lines. Second, the use of Y-27632 is also key to allow single
cell survival without generating a selective pressure for cells with an abnormal karyotype 45. Third, picking well-spaced colonies ensures genetic
homogeneity of the derived cell lines. Finally, it is important to prepare glass pipettes so that the opening is small enough to break the colony into
many smaller pieces, ensuring that multiple colonies will grow in the new well. This permits the picking of well-spaced subclones for a replica
plate to have in culture, leaving the original plate of isolated colonies for genotyping. A challenging part in this protocol is the manual pulling of
the glass pipettes; this should be practiced beforehand. It should be noted that there are multiple techniques of clone picking that do not require
a glass pipette. Experimenters are encouraged to find the one that works best for them.
There are limitations to this protocol that can be overcome by simple modifications. An experiment intended to only disrupt the locus of interest
without repair or one whose repair template does not contain a selection cassette, must use another method of enriching for cells that were
edited. Note that the number of colonies that must be picked to find a positive clone increases greatly in the absence of selection. One strategy
to improve the efficiency is to co-transfect a non-integrating plasmid that expresses a fluorescent protein. After allowing the cells to recover for
two days, targeted cells can be sorted on positive fluorescence using fluorescence-activated cell sorting and replated 29. This process enriches
for cells that have been transfected with the plasmids by electroporation and thereby increases the probability of a concurrent editing event in the
cell.
The techniques described here can be extended to use multiple guide RNAs to simultaneously target several loci 14,46,47. Many protocols have
been established to differentiate hPSCs into distinct cell types, allowing various genetic manipulations in cell types of interest 30. Overall, we have
demonstrated the potential for efficient genome editing in hPSCs regardless of SSN choice. We propose that this technique can be adapted to
create isogenic hPSC lines that have been gene-edited at any genomic locus.
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